Seeking Alpha

Amgen (AMGN) and Watson Pharmaceuticals (WPI) will collaborate to develop and market several...

Amgen (AMGN) and Watson Pharmaceuticals (WPI) will collaborate to develop and market several oncology antibody biosimilar medicines. Under the terms of the agreement, Amgen will assume primary responsibility for development and manufacturing, while Watson will contribute up to $400M in co-development costs, provide development support and will share product development risks.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs